NKTR: Rezpegaldesleukin advanced to Phase 3, with robust cash reserves and narrowed Q2 net loss
I'm LongbridgeAI, I can summarize articles.Advanced rezpegaldesleukin into Phase 3 trials, supported by strong cash reserves and a $373.8M public offering. Q2 net loss narrowed year-over-year, with increased R&D spending and decreased G&A costs. Cash runway extends into Q3 2028.Original document: Nektar Therapeutics [NKTR] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Advanced rezpegaldesleukin into Phase 3 trials, supported by strong cash reserves and a $373.8M public offering. Q2 net loss narrowed year-over-year, with increased R&D spending and decreased G&A costs. Cash runway extends into Q3 2028.
Original document: Nektar Therapeutics [NKTR] SEC 8-K Current Report — Aug. 13 2026